{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Td+%28Tetanus+diphtheria%29+vaccine&page=2",
    "query": {
      "intervention": "Td (Tetanus diphtheria) vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 29,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Td+%28Tetanus+diphtheria%29+vaccine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Td+%28Tetanus+diphtheria%29+vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T20:40:49.808Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00297856",
      "title": "Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diphtheria",
        "Tetanus",
        "Acellular Pertussis"
      ],
      "interventions": [
        {
          "name": "Boostrix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td (Tetanus diphtheria) vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 10000,
      "start_date": "2006-03",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00297856"
    },
    {
      "nct_id": "NCT00601835",
      "title": "Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diphtheria",
        "Tetanus"
      ],
      "interventions": [
        {
          "name": "Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "11 Years to 60 Years"
      },
      "enrollment_count": 3651,
      "start_date": "2004-05",
      "completion_date": "2005-07",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00601835"
    },
    {
      "nct_id": "NCT06254326",
      "title": "ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Oligodendroglioma",
        "Progressive Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "TTRNA-DC vaccines with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Stem cells (HSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TTRNA-xALT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-09-19",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254326"
    },
    {
      "nct_id": "NCT06514898",
      "title": "Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Group 3 Medulloblastoma",
        "Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "TTRNA-DC vaccines with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TTRNA-xALT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td vaccine",
          "type": "DRUG"
        },
        {
          "name": "autologous HSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "4 Years to 30 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-05-05",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06514898"
    },
    {
      "nct_id": "NCT05096481",
      "title": "PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Diffuse Intrinsic Pontine Glioma",
        "Recurrent Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "PEP-CMV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Tetanus Diphtheria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-07-18",
      "completion_date": "2030-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 13,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096481"
    },
    {
      "nct_id": "NCT03615404",
      "title": "Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Malignant Glioma",
        "Medulloblastoma Recurrent",
        "Pediatric Glioblastoma Multiforme",
        "Pediatric Brain Tumor, Recurrent",
        "Pediatric Brain Tumor"
      ],
      "interventions": [
        {
          "name": "CMV-DCs with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td (tetanus toxoid)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gary Archer Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "0 Years to 35 Years"
      },
      "enrollment_count": 11,
      "start_date": "2018-10-05",
      "completion_date": "2020-07-02",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615404"
    },
    {
      "nct_id": "NCT02673255",
      "title": "Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tetanus and Diphtheria (Td) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomat USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 300,
      "start_date": "2016-08-22",
      "completion_date": "2019-07-29",
      "has_results": false,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 4,
      "location_summary": "Bellflower, California • Lincoln, Nebraska • Clarksville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Clarksville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02673255"
    },
    {
      "nct_id": "NCT05095844",
      "title": "National Vaccine Adverse Event Reporting Survey and Etiology",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID-19",
        "Vaccine Adverse Reaction",
        "Vaccine Reaction",
        "Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use",
        "Corona Virus Infection",
        "Blood Clot",
        "Thrombocytopenia",
        "Neuritis",
        "Vasculitis",
        "Influenza",
        "Guillain-Barré",
        "GWAS",
        "Genetic Sequencing"
      ],
      "interventions": [
        {
          "name": "vaccinated",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neuroganics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "5 Years to 99 Years"
      },
      "enrollment_count": 100000,
      "start_date": "2022-03-15",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 1,
      "location_summary": "Northglenn, Colorado",
      "locations": [
        {
          "city": "Northglenn",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05095844"
    },
    {
      "nct_id": "NCT00164411",
      "title": "Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "Tetanus-diphtheria toxoids (Td)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7-valent pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23-valent polysaccharide vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-01",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00164411"
    },
    {
      "nct_id": "NCT00128219",
      "title": "Prevention of GBS Colonization Via Immunity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta Haemolytic Streptococcal Infection"
      ],
      "interventions": [
        {
          "name": "GBS III-TT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus and diptheria toxoids vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 667,
      "start_date": "2003-07",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-10-05T20:40:49.808Z",
      "location_count": 3,
      "location_summary": "Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00128219"
    }
  ]
}